• 제목/요약/키워드: ERB

검색결과 121건 처리시간 0.028초

두경부 편평세포암종에서 p53, p21, EGFR 및 c-erbB-2 발현의 임상적 의의 (Clinical Significance of the Expression of p53, p21, EGFR and c-erbB-2 in Squamous Cell Carcinoma of the Head and Neck)

  • 이준한;도남용;박성용;김건형;조성일
    • 대한두경부종양학회지
    • /
    • 제21권2호
    • /
    • pp.139-145
    • /
    • 2005
  • Background and Objectives: Because of squamous cell carcinoma of the head and neck undergoes a generally poor hospital course, the prognostic significance of the squamous cell carcinomas in head and neck have been evaluated to identify those features associated with aggressive biologic behavior according to the immunologic and histopathologic characteristics. Materials and Method: To assess the significance of EGFR, c-erbB-2, p21 and p53 protein in head and neck tumors and their correlation with prognostic factors, samples from 74 patients with squamous cell carcinomas of larynx, pharynx, and oral cavity were studied immunohistochemically. Results: EGFR, c-erbB-2, p21, and p53 protein were expressed 94.6%, 24.3%, 85.1%, and 55.4% in 74 cases of head and neck squamous cell carcinoma, respectively. The positive expression of EGFR was associated significantly with clinical stage and the negative expressions of p21 was associated significantly with histopathologic differentiation. There were no significant relationships between the reactivity of EGFR, c-erbB-2, p21, and p53 protein. Conclusion: The expression of EGFR, c-erbB-2, p21 and p53 protein could be related to oncogenesis, and the expression of p21 and EGFR protein can be used as a prognosticator in head and neck squamous cell carcinoma under certain limitations, but c-erbB-2 and p53 protein expression alone is not enough for evaluating prognosis of the carcinoma.

Evaluation of c-erbB2/neu Oncogene Status in Canine Mammary Tumors on Tissue Microarray

  • Kang, Jong-il;Cho, Ho-seong;A.W.M. Effendy;Park, Nam-yong
    • 한국수의병리학회:학술대회논문집
    • /
    • 한국수의병리학회 2003년도 추계학술대회초록집
    • /
    • pp.40-40
    • /
    • 2003
  • The c-erbB2/neu oncogene (alias HER2, NEU) encoding a tyrosine kinase receptor protein, the overexpression of which correlates with a more rapid progression and a worse prognosis in human breast cancer [1]. Otherwise, this gene is still poorly investigated in veterinary oncology [2,3]. To gain insight into the patterns of c-erbB2/neu status in canine mammary tumor, we constructed one such mammary tumor tissue microarray (TMA) from 60 tumors from our lab. This enabled the amplification of c-erbB2/neu oncogene of all 60 tumors to be simultaneously analyzed by chromogenic in situ hybridization (CISH). The aim of this study was to evaluate status of c-erbB2/neu oncogene in canine mammary tumors and to correlate this status with the differentiation grade of neoplasm. (omitted)

  • PDF

Sinapic Acid Ameliorates REV-ERB α Modulated Mitochondrial Fission against MPTP-Induced Parkinson's Disease Model

  • Lee, Sang-Bin;Yang, Hyun Ok
    • Biomolecules & Therapeutics
    • /
    • 제30권5호
    • /
    • pp.409-417
    • /
    • 2022
  • Parkinson's disease (PD) is the second most common neurodegenerative disease worldwide, and accumulating evidence indicates that mitochondrial dysfunction is associated with progressive deterioration in PD patients. Previous studies have shown that sinapic acid has a neuroprotective effect, but its mechanisms of action remain unclear. The neuroprotective effect of sinapic acid was assayed in a PD mouse model generated by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) as well as in SH-SY5Y cells. Target protein expression was detected by western blotting. Sinapic acid treatment attenuated the behavioral defects and loss of dopaminergic neurons in the PD models. Sinapic acid also improved mitochondrial function in the PD models. MPTP treatment increased the abundance of mitochondrial fission proteins such as dynamin-related protein 1 (Drp1) and phospho-Drp1 Ser616. In addition, MPTP decreased the expression of the REV-ERB α protein. These changes were attenuated by sinapic acid treatment. We used the pharmacological REV-ERB α inhibitor SR8278 to confirmation of protective effect of sinapic acid. Treatment of SR8278 with sinapic acid reversed the protein expression of phospho-Drp1 Ser616 and REV-ERB α on MPTP-treated mice. Our findings demonstrated that sinapic acid protects against MPTP-induced PD and these effects might be related to the inhibiting abnormal mitochondrial fission through REV-ERB α.

Hesa-A Down-Regulates erb/b2 Oncogene Expression and Improves Outcome of Oral Carcinoma in a Rat Model

  • Abbasi, Mehran Mesgari;Mehdipour, Masoumeh;Monfaredan, Amir;Jahanban-Esfahlan, Rana
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권16호
    • /
    • pp.6947-6951
    • /
    • 2015
  • Background: Oral carcinoma (OC) remains one of the most difficult malignancies to cure. Hesa-A is an Iranian herbal-marine compound that has shown promising anti-tumor properties against various human tumors. However, its mechanism of action remains to be addressed. The present study was conducted to evaluate the effect of two doses of Hesa-A on mRNA expression of erb$\backslash$b2 as a main prognosticator tumor marker for OC in an animal model. Materials and Methods: A total of 60 rats were randomly divided into 5 groups of 12 animals each. Rats in carcinoma groups received 0, 250 and 500mg/kg body weight doses of Hesa-A 3 times a day. The other two groups were considered as treated and untreated control groups. At the end of the experiment, animals were sacrificed and tongue tissues subjected to H and E staining and real time PCR. Results: Our results showed that compared to the control group, erb$\backslash$b2 was over-expressed ~ 30% in the carcinoma group. After treatment with 250mg/kg and 500mg/kg body weight of Hesa-A, erb$\backslash$b2 levels dropped by 24.1% and 3.4 % respectively compared to the control carcinoma group (p<0.01, p<0.0001). Moreover, there was a significant relation between erb$\backslash$b2 mRNA content and observed pathological changes in studied groups (p<0.05). Conclusions: These data provide insight into mechanism(s) by which Hesa-A may improve clinical outcome of oral carcinoma by affecting oncogene erb$\backslash$b2 expression and suggest Hesa-A as an effective chemotherapeutic agent in treatment of HER+tumors.

ErbB 수용체를 이용한 난소암세포 표적 유전자치료 벡터의 개발 (Development of the Gene Therapy Vector for Targeting Ovarian Cancer Cells through ErbB Receptors)

  • 정인실;방성호
    • 미생물학회지
    • /
    • 제47권1호
    • /
    • pp.1-6
    • /
    • 2011
  • 암의 유전자치료에서 암세포로의 선택적 유전자전달 매체의 부족은 치료효과의 감소를 야기하는 문제이다. 본 연구에서는 난소암 유전자치료의 효율을 높이기 위한 목적으로 난소암세포로 선택적인 유전자전달을 하도록 개량된 아데노바이러스 벡터를 제조하고, 그 효율성을 난소암세포주를 이용하여 조사하였다. 난소암세포에 과다발현하는 분자인 ErbB receptor를 표적하도록 아데노바이러스 외피단백질 fiber에 ErbB receptor에 대한 ligand인 heregulin으로부터 유래한 펩티드를 부착하였다. 53개의 아미노산으로 구성된 외부 펩티드를 fiber에 부착하였을 때 바이러스 감염에 중요한 기능을 하는 fiber 삼량체 구조 형성에 영향을 미치지 않았다. Fiber를 조작한 개량 아데노바이러스는 야생형 fiber를 가진 1세대 아데노바이러스 벡터에 비해 선택적으로 난소암으로 유전자를 전달하는 비율이 증가하였다. 특히 항암제에 저항성을 가진 난소암세포주 OVCAR3에서 유전자전달 효율이 약 5배 증가되었다. 따라서 난소암의 유전자치료에서 개량된 아데노바이러스로 치료 유전자를 전달하면 치료의 효율성을 향상시킬 수 있을 것이다.

구강 편평세포암에서 EGFR과 C-erb-B2 유전자 발현에 관한 면역조직화학적 연구 (IMMUNOHISTOCHEMICAL ANALYSIS OF EGFR AND C-ERB-B2 GENE EXPRESSION OF SQUAMOUS CELL CARCINOMA IN ORAL CAVITY)

  • 조원;조재식;이종원;김해송;박근재
    • 대한기관식도과학회지
    • /
    • 제2권2호
    • /
    • pp.200-212
    • /
    • 1996
  • The clinical staging systems for oral squamous cell carcinoma is limited as a prognostic indicatior because of different biological characteristics of cancer in this region and variable microenvironment depending on subsites, there have been study to determine prognosis by evaluating malignancy, that is the nature of tumor cells. Many studies have been tried to determine prognostic indicator in various malignancies for the evaluation of differentiation capacity and the expression of oncogene product. EGF make a role in cellular growth and differentiation and to be essential in cellular survival. EGFR is an intergral membrane protein, stimulate cellular differentiation and hormonal secretion, and has structural homology with V-erb-B transforming protein. Recent reports have demonstrated that EGFR is overexpressed in stomach, breast, vagina, dermis, head and neck, genitourinary and lung tumors, and possibly used as a tumor marker. In head and neck region, most of studies were mainly carried out on laryngeal squamous cell carcinoma. In the present study, immunohistochemical study for EGFR and C-erb-B2 gene in paraffin sections of 45 squamous cell carcinoma in oral cavity was performed to evaluate the presense of EGFR and C- erb-B2 gene in this lesion, to evaluate them as a prognostic indicator by analysing the correlation between these expression and subsites, primary stages, clinical stages, pathologic grades, neck node metastasis, recurrences and treatment results, and to determine relation between EGFR and C-erb-B2 gene.

  • PDF

ERB 필터를 이용한 시맨틱 온톨로지 음성 인식 성능 향상 (Semantic Ontology Speech Recognition Performance Improvement using ERB Filter)

  • 이종섭
    • 디지털융복합연구
    • /
    • 제12권10호
    • /
    • pp.265-270
    • /
    • 2014
  • 기존의 음성 인식 알고리즘은 어휘들 간의 순서가 정해져 있지 않으며, 음성 인식 환경 변화에 따른 잡음으로 인한 음성 검출이 정확하지 못한 단점을 가지며, 검색 시스템은 키워드의 의미가 다양하여 정확한 정보를 인지하지 못한다. 본 연구에서는 사건 기반 시맨틱 온톨로지 추론 모델을 제안하였으며, 제안된 시스템에서 음성 인식 특징을 추출하기 위해 ERB 필터를 이용하여 특징 추출하는 모델을 구축하였다. 제안된 모델은 성능 평가를 위해 지하철역, 지하철 잡음을 사용하였고 잡음 환경의 SNR -10dB, -5dB 신호에서 잡음 제거를 수행하여 왜곡도를 측정한 결과 2.17dB, 1.31dB의 성능이 향상됨을 확인하였다.

수술을 시행한 비소세포 폐암 환자에서 EGFR, MMP-9 및 C-erbB-2의 발현과 환자 생존율과의 관계 (The Relationship between Expression of EGFR, MMP-9, and C-erbB-2 and Survival Time in Resected Non-Small Cell Lung Cancer)

  • 이승헌;정진용;이경주;이승현;김세중;하은실;김정하;이은주;허규영;정기환;정혜철;이승룡;이상엽;김제형;신철;심재정;인광호;강경호;유세화;김철환
    • Tuberculosis and Respiratory Diseases
    • /
    • 제59권3호
    • /
    • pp.286-297
    • /
    • 2005
  • 서 론 : 비소세포 폐암은 악성 종양 관련 사망의 중요한 원인 질환으로, 주요 병태생리 기전에 관여하는 EGFR, MMP-9 및 C-erbB-2의 발현 양상을 관찰 하는 것이 환자의 예후와 향후 치료 방향을 결정하는데 도움이 될 수 있다. 방 법 : 1995년 부터 2001년 까지 고려 대학교 의료원에 내원 후 원발성 비소세포 폐암 확진 후 외과절제술을 받은 81명 환자의 조직에 EGFR, MMP-9 및 C-erbB-2 면역 조직 화학 염색 및 정량화 후, 환자들의 특성 및 생존 기간과 함께, 조직 및 수술 병기에 따른 생물학적 표지자의 발현 양상을 후향적 고찰 하였다. 결 과 : 각 종양 조직 부위의 20%이상 염색되는 Grade 2 이상의 염색 양성률은, 편평상피세포암과 선암에서 EGFR은 75.0%와 63.4%, MMP-9은 43.3%와 43.9%, C-erbB-2는 23.3%와 22.0%를 보였다. 수술 병기가 I, II, IIIa 일때 EGFR 염색 양성률은 각각 75.0%, 66.7%, 76.9%, MMP-9은 41.7%, 47.6%, 46.2%, 그리고 C-erbB-2는 19.4%, 40.0%, 30.8%를 보였다. EGFR 양성군은 중앙 생존기간이 33.5개월로 EGFR 음성군의 71.8개월보다 유의한 불량한 예후를 나타냈다.(p<0.05). 그리고 MMP-9 양성군은 중앙 생존기간 35개월로 MMP-9 음성군의 65.3개월보다 불량한 생존 곡선의 양상을 보였으나 통계적 유의성은 없었다. 또한 C-erbB-2 양성군은 중앙 생존기간이 44.2개월, C-erbB-2 음성군은 58.4개월을 나타냈으나 통계적 유의한 차이는 없었다. EGFR과 MMP-9 동시 양성군은 전체 환자의 34.2%로서 중앙 생존기간이 26.9개월로 EGFR과 MMP-9 동시 음성군의 77.0개월보다 유의한 불량한 예후를 나타냈다(p<0.05) 결 론 : 비소세포 폐암 에서 EGFR의 양성군에서 음성군 보다 환자의 생존기간이 불량하였고, EGFR과 MMP-9의 동시 양성군에서 동시 음성군보다 생존기간이 불량하였다. C-erbB-2는 다른 생물학적 표지자에 비해서 낮은 염색 양성률을 나타냈으며 특이한 상관관계는 보이지 않았다.

Anti-metastasis Activity of Black Rice Anthocyanins Against Breast Cancer: Analyses Using an ErbB2 Positive Breast Cancer Cell Line and Tumoral Xenograft Model

  • Luo, Li-Ping;Han, Bin;Yu, Xiao-Ping;Chen, Xiang-Yan;Zhou, Jie;Chen, Wei;Zhu, Yan-Feng;Peng, Xiao-Li;Zou, Qiang;Li, Sui-Yan
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권15호
    • /
    • pp.6219-6225
    • /
    • 2014
  • Background: Increasing evidence from animal, epidemiological and clinical investigations suggest that dietary anthocyanins have potential to prevent chronic diseases, including cancers. It is also noteworthy that human epidermal growth factor receptor 2 (ErbB2) protein overexpression or ErbB2 gene amplification has been included as an indicator for metastasis and higher risk of recurrence for breast cancer. Materials and Methods: The present experiments investigated the anti-metastasis effects of black rice anthocyanins (BRACs) on ErbB2 positive breast cancer cells in vivo and in vitro. Results: Oral administration of BRACs (150 mg/kg/day) reduced transplanted tumor growth, inhibited pulmonary metastasis, and decreased lung tumor nodules in BALB/c nude mice bearing ErbB2 positive breast cancer cell MDA-MB-453 xenografts. The capacity for migration, adhesion, motility and invasion was also inhibited by BRACs in MDA-MB-453 cells in a concentration dependent manner, accompanied by decreased activity of a transfer promoting factor, urokinase-type plasminogen activator (u-PA). Conclusions: Together, our results indicated that BRACs possess anti-metastasis potential against ErbB2 positive human breast cancer cells in vivo and in vitro through inhibition of metastasis promoting molecules.